Identification of Drivers from Cancer Genome Diversity in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the most common cancers with a dismal outcome. The complicated molecular pathogenesis of HCC caused by tumor heterogeneity makes it difficult to identify druggable targets useful for treating HCC patients. One approach that has a potential for the improvemen...

Full description

Bibliographic Details
Main Authors: Atsushi Takai, Hien T. Dang, Xin W. Wang
Format: Article
Language:English
Published: MDPI AG 2014-06-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:http://www.mdpi.com/1422-0067/15/6/11142
id doaj-f8f16ae6edea46878577d114edfd1e46
record_format Article
spelling doaj-f8f16ae6edea46878577d114edfd1e462020-11-25T00:48:55ZengMDPI AGInternational Journal of Molecular Sciences1422-00672014-06-01156111421116010.3390/ijms150611142ijms150611142Identification of Drivers from Cancer Genome Diversity in Hepatocellular CarcinomaAtsushi Takai0Hien T. Dang1Xin W. Wang2Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USALaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USALaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USAHepatocellular carcinoma (HCC) is one of the most common cancers with a dismal outcome. The complicated molecular pathogenesis of HCC caused by tumor heterogeneity makes it difficult to identify druggable targets useful for treating HCC patients. One approach that has a potential for the improvement of patient prognosis is the identification of cancer driver genes that play a critical role in the development of HCC. Recent technological advances of high-throughput methods, such as gene expression profiles, DNA copy number alterations and somatic mutations, have expanded our understanding of the comprehensive genetic profiles of HCC. Integrative analysis of these omics profiles enables us to classify the molecular subgroups of HCC patients. As each subgroup classified according to genetic profiles has different clinical features, such as recurrence rate and prognosis, the tumor subclassification tools are useful in clinical practice. Furthermore, a global genetic analysis, including genome-wide RNAi functional screening, makes it possible to identify cancer vulnerable genes. Identification of common cancer driver genes in HCC leads to the development of an effective molecular target therapy.http://www.mdpi.com/1422-0067/15/6/11142hepatocellular carcinomatumor heterogeneitycancer driver gene
collection DOAJ
language English
format Article
sources DOAJ
author Atsushi Takai
Hien T. Dang
Xin W. Wang
spellingShingle Atsushi Takai
Hien T. Dang
Xin W. Wang
Identification of Drivers from Cancer Genome Diversity in Hepatocellular Carcinoma
International Journal of Molecular Sciences
hepatocellular carcinoma
tumor heterogeneity
cancer driver gene
author_facet Atsushi Takai
Hien T. Dang
Xin W. Wang
author_sort Atsushi Takai
title Identification of Drivers from Cancer Genome Diversity in Hepatocellular Carcinoma
title_short Identification of Drivers from Cancer Genome Diversity in Hepatocellular Carcinoma
title_full Identification of Drivers from Cancer Genome Diversity in Hepatocellular Carcinoma
title_fullStr Identification of Drivers from Cancer Genome Diversity in Hepatocellular Carcinoma
title_full_unstemmed Identification of Drivers from Cancer Genome Diversity in Hepatocellular Carcinoma
title_sort identification of drivers from cancer genome diversity in hepatocellular carcinoma
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1422-0067
publishDate 2014-06-01
description Hepatocellular carcinoma (HCC) is one of the most common cancers with a dismal outcome. The complicated molecular pathogenesis of HCC caused by tumor heterogeneity makes it difficult to identify druggable targets useful for treating HCC patients. One approach that has a potential for the improvement of patient prognosis is the identification of cancer driver genes that play a critical role in the development of HCC. Recent technological advances of high-throughput methods, such as gene expression profiles, DNA copy number alterations and somatic mutations, have expanded our understanding of the comprehensive genetic profiles of HCC. Integrative analysis of these omics profiles enables us to classify the molecular subgroups of HCC patients. As each subgroup classified according to genetic profiles has different clinical features, such as recurrence rate and prognosis, the tumor subclassification tools are useful in clinical practice. Furthermore, a global genetic analysis, including genome-wide RNAi functional screening, makes it possible to identify cancer vulnerable genes. Identification of common cancer driver genes in HCC leads to the development of an effective molecular target therapy.
topic hepatocellular carcinoma
tumor heterogeneity
cancer driver gene
url http://www.mdpi.com/1422-0067/15/6/11142
work_keys_str_mv AT atsushitakai identificationofdriversfromcancergenomediversityinhepatocellularcarcinoma
AT hientdang identificationofdriversfromcancergenomediversityinhepatocellularcarcinoma
AT xinwwang identificationofdriversfromcancergenomediversityinhepatocellularcarcinoma
_version_ 1725254152524660736